Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | New therapies for mantle cell lymphoma

Umberto Vitolo • 5 Dec 2014
ASH 2014
Mantle Cell Lymphoma Ibrutinib Lenalidomide

Prof Umberto Vitolo (Città della Salute e della Scienza di Torino, Turin, Italy) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses new therapies for mantle cell lymphoma, including biologic approaches with lenalidomide plus rituximab, ibrutinib and ABT-199.

More from Umberto Vitolo

1:56
Copanlisib, rituximab, & bendamustine in transplant-ineligible R/R DLBCL
Umberto Vitolo • 10 Dec 2023
2:13
Rituximab ± lenalidomide as maintenance therapy in elderly patients with R/R FL
Umberto Vitolo • 10 Dec 2023
3:20
Bispecific antibodies in NHL: current insights and ongoing studies
Umberto Vitolo • 15 Jun 2023
1:31
The current state of treatment for limited-stage DLBCL
Umberto Vitolo • 15 Jun 2023

Related Videos

3:32
BGB-16673, a novel BTK degrader, in patients with R/R B-cell malignancies
John Seymour • 8 Dec 2023
2:25
The future of CAR-T for the treatment of lymphoma
Anna Sureda • 7 Mar 2024
2:40
The impact of CAR-T on the role of SCT in lymphoma
Anna Sureda • 7 Mar 2024
0:44
A case report of CAR-T-related neurotoxicity presenting as delayed aseptic meningitis in MCL
Stefania Bramanti • 17 Feb 2024
The content of VJHemOnc is intended for healthcare professionals